Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oglemilast

Drug Profile

Oglemilast

Alternative Names: GRC 3886; GRC-3836

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Developer Forest Laboratories; Glenmark Pharmaceuticals Ltd
  • Class Antiallergics; Antiasthmatics; Benzofurans; Pyridines; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease
  • Discontinued Exercise-induced asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom (PO)
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top